High-Dose Ubiquinol for Multiple System Atrophy Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for multiple system atrophy (MSA) are ineffective in suppressing symptom progression, and there is a lack of effective treatments for both familial and sporadic MSA patients, with existing clinical trials showing only minor and non-statistically significant therapeutic effects.
Innovation Solution
A pharmaceutical composition involving repeated oral administration of ubiquinol at high doses (1,500 to 1,800 mg per day for 7 days or more, aiming to achieve a maximum plasma concentration of 10 μg/mL or more, to alleviate and suppress MSA symptoms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional doses of ubiquinol are administered to MSA patients, then safety is maintained, but therapeutic effect is insufficient or non-significant
Solution Approach 1:
The patent applies parameter changes by increasing the ubiquinol dosage from conventional levels (600-1200 mg/day) to high doses (1500-1800 mg/day) and extending the treatment duration to 7 days or more, thereby transforming the dosage parameters to achieve statistically significant therapeutic effects in MSA patients
Solution Approach 2:
The patent employs excessive action by administering ubiquinol at doses exceeding conventional recommendations (1500-1800 mg/day, which is 1.25-3 times higher than standard doses), thereby overcoming the insufficient therapeutic effect observed with normal dosing regimens
2Reliability
If high dose ubiquinol is administered for short duration, then dosage intensity is achieved, but cumulative therapeutic effect is insufficient
Solution Approach 1:
The patent implements continuity of useful action by maintaining high-dose ubiquinol administration for extended periods of 7 days or more, ensuring continuous therapeutic action that accumulates to produce statistically significant clinical effects, rather than using short-term intermittent dosing
3Stability of the object's composition
If ubiquinone is administered instead of ubiquinol, then stability is improved, but bioavailability and direct therapeutic action are reduced
Solution Approach 1:
The patent uses ubiquinol as an intermediary form that, when administered orally, is converted by intestinal flora into active ubiquinol in the plasma, thereby solving the stability issue while ensuring adequate bioavailability and therapeutic action through the intermediary conversion process
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively relieves and suppresses the progression of MSA symptoms, as demonstrated by significant improvements in clinical trial outcomes, including improved brain oxygen consumption and mitochondrial function, offering a previously unexperienced level of symptom alleviation.
Implementation Method 1
The ubiquinone is converted to the ubiquinol by reductases such as a NADPH-dependent CoQ reductase, a DT diaphorase, a lipoamide dehydrogenase, and a thioredoxin reductase present in cytoplasm
Implementation Method 2
Coenzyme Q10 includes an oxidized form (ubiquinone) and a reduced form (ubiquinol), and the ubiquinol exhibits a pharmacological action in vivo
Data Source
AI summary
Provided is a pharmaceutical composition that can treat multiple system atrophy by alleviating or suppressing the progression of the various symptoms caused by multiple system atrophy. Provided is a pharmaceutical composition for treatment of multiple system atrophy, the composition containing ubiquinol, in which the ubiquinol is subjected to oral administration repeatedly for 7 days or more at a dose of 1,500 to 1,800 mg per day.